Market Cap (In USD)
1.38 Billion
Revenue (In USD)
983.7 Million
Net Income (In USD)
-545.06 Million
Avg. Volume
6.66 Million
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 3.53-23.86
- PE
- -
- EPS
- -
- Beta Value
- 2.088
- ISIN
- US6700024010
- CUSIP
- 670002401
- CIK
- 1000694
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. John Charles Jacobs M.B.A.
- Employee Count
- -
- Website
- https://www.novavax.com
- Ipo Date
- 1995-12-05
- Details
- Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
More Stocks
-
AAL
-
WFSTF
-
6820Icom Incorporated
6820
-
TR
-
LNR
-
474490Yuanta SPAC 16
474490
-
BVA
-
ANTMFAntilles Gold Limited
ANTMF